Posted on July 20, 2019 in ASRC in the News, Neuroscience Initiative
The National Multiple Sclerosis Society has featured a recent paper published by researchers at the Advanced Science Research Center (ASRC) at The Graduate Center, CUNY and Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai, investigating how differences in the cerebrospinal fluid of MS patients may hold the key to therapies that halt progression.
Collaborating researchers from New York City report that the spinal fluid of people with progressive MS dramatically inhibited the ability of rodent nerve cells isolated in lab dishes to produce energy, while spinal fluid from people with relapsing-remitting MS did not.